Advertisement
PRFX vs SUPN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRFX is a Buy and SUPN is a StrongBuy.
PRFX's RSI Indicator climbs out of oversold territory
The RSI Oscillator for PRFX moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 52 similar instances when the indicator left oversold territory. In 48 of the 52 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 152 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PRFX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRFX as a result. In 97 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PRFX turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 51 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PRFX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.168) is normal, around the industry mean (11.138). P/E Ratio (-0.187) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
SUPN in upward trend: price may jump up because it broke its lower Bollinger Band on October 14, 2026
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 34 cases where SUPN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SUPN's RSI Oscillator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +8.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 227 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SUPN as a result. In 71 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for SUPN turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 36 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.327) is normal, around the industry mean (11.138). P/E Ratio (-21.464) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PRFX | SUPN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 34 Fair valued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 57 | |
SMR RATING 1..100 | 98 | 94 | |
PRICE GROWTH RATING 1..100 | 92 | 71 | |
P/E GROWTH RATING 1..100 | 100 | 98 | |
SEASONALITY SCORE 1..100 | 11 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRFX's Valuation (34) in the null industry is in the same range as SUPN (40) in the Pharmaceuticals Other industry. This means that PRFX’s stock grew similarly to SUPN’s over the last 12 months.
SUPN's Profit vs Risk Rating (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for PRFX (100) in the null industry. This means that SUPN’s stock grew somewhat faster than PRFX’s over the last 12 months.
SUPN's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as PRFX (98) in the null industry. This means that SUPN’s stock grew similarly to PRFX’s over the last 12 months.
SUPN's Price Growth Rating (71) in the Pharmaceuticals Other industry is in the same range as PRFX (92) in the null industry. This means that SUPN’s stock grew similarly to PRFX’s over the last 12 months.
SUPN's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as PRFX (100) in the null industry. This means that SUPN’s stock grew similarly to PRFX’s over the last 12 months.
| PRFX | SUPN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| Advances ODDS (%) | 8 days ago 83% | 3 days ago 72% |
| Declines ODDS (%) | 3 days ago 90% | 7 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PRFX’s FA Score shows that 0 FA rating(s) are green while SUPN’s FA Score has 0 green FA rating(s).
- PRFX’s FA Score: 0 green, 5 red.
- SUPN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PRFX’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).
- PRFX’s TA Score: 4 bullish, 4 bearish.
- SUPN’s TA Score: 4 bullish, 4 bearish.
Price Growth
PRFX (@Pharmaceuticals: Generic) experienced а -7.03% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +2.56% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
PRFX is expected to report earnings on Nov 19, 2026.
SUPN is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement